What is not an appropriate response to a protocol violation: reducing sample size, documenting and reporting to Institutional Review Board (IRB), or addressing participant safety concerns?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The correct answer is C, as reducing the study sample size in order to minimize future protocol violations is not an appropriate response to a protocol violation occurrence. When a protocol violation happens during a clinical trial, proper responses include:

  • Documenting the violation along with any corrective actions taken
  • Reporting the violation to the Institutional Review Board (IRB) that oversees the study, as emphasized by the importance of IRB policies in adapting to extraordinary circumstances such as the COVID-19 pandemic 1
  • Immediately addressing any participant safety concerns related to the violation

Reducing the sample size is inappropriate because it compromises the scientific integrity and statistical power of the study, potentially invalidating the research findings. Additionally, reducing sample size doesn't actually address the root cause of the violation or prevent similar issues in the future. Instead, protocol violations should trigger a thorough review of procedures, additional training for staff if needed, and implementation of preventive measures while maintaining the study's scientific validity and participant safety. The SPIRIT 2013 Statement provides a guideline for the minimum content of a clinical trial protocol, emphasizing the importance of a well-written protocol in facilitating an appropriate assessment of scientific, ethical, and safety issues before a trial begins 1.

In the context of clinical trials, maintaining the study's scientific validity and participant safety is crucial, and reducing the sample size does not align with these goals. Therefore, option C is the correct answer, as it is not an appropriate response to a protocol violation occurrence.

From the Research

Protocol Violation Response

The following options are potential responses to a protocol violation occurrence:

  • Document the violation and corrective action
  • Report the violation to the affiliated IRB
  • Immediately address any concerns regarding participant safety related to the violation

Inappropriate Response

The option that is NOT an appropriate response to a protocol violation occurrence is:

  • Reduce the study sample size in order to minimize future protocol violations

There are no research papers provided that directly address the appropriate response to a protocol violation occurrence in the context of GCP certification 2, 3, 4, 5, 6.

Related Questions

What key principles of human research protections did the Belmont Report of 1979 establish?
What personnel may be included in the staff at a research site, such as Research Assistants (RAs), Therapists/Counselors, or the Principal Investigator (PI)?
What is the required timeframe for site staff to report an unexpected serious adverse event (SAE) to the Sponsor after becoming aware of the event?
What type of studies are conducted to examine the long-term safety of a drug after it has been approved for marketing by the Food and Drug Administration (FDA)?
What is not an appropriate response to a protocol violation: reducing sample size, documenting and reporting to Institutional Review Board (IRB), or addressing participant safety concerns?
Must every aspect of a research study be documented in compliance with Good Clinical Practice (GCP) guidelines to obtain useful data?
What clinical, pathological, and molecular characteristics are associated with the addition of anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) therapy in non-small cell lung cancer?
What clinical, pathological, and molecular characteristics are associated with the addition of anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) therapy in non-small cell lung cancer?
What is the cause of heel pain localized to the medial tuberosity (medial tuberosity of the calcaneus) for 2 months without any history of injury?
When must a research protocol be approved by an Institutional Review Board (IRB) for Good Clinical Practice (GCP) certification?
What clinical, pathological, and molecular characteristics are associated with the addition of anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) therapy in non-small cell lung cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.